The Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors and Its Change from 1990 to 2019: a Systematic Analysis and Prediction

Overview

Journal Front Epidemiol

Specialty Public Health

Date 2024 Mar 8

PMID 38455920

Authors

Huaigen Wang

Jing Liu

Yunfei Feng

Aiqun Ma

Tingzhong Wang

Affiliations

Soon will be listed here.

Abstract

Background: Metabolic disorders are the most important risk factors for cardiovascular diseases (CVDs). The purpose of this study was to systematically analyze and summarize the most recent data by age, sex, region, and time, and to forecast the future burden of diseases.

Methods: Data on the burden of CVDs associated with metabolic risk factors were obtained from the Global Burden of Disease (GBD) Study 2019; and then the burden of disease was assessed using the numbers and age-standardized rates (ASR) of deaths, years of life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs) and analyzed for temporal changes, differences in age, region, sex, and socioeconomic aspects; finally, the burden of disease was predicted using an autoregressive integrated moving average (ARIMA) model.

Results: From 1990 to 2019, the numbers of deaths, DALYs, YLDs, and YLLs attributed to metabolic risk factors increased by 59.3%, 51.0%, 104.6%, and 47.8%, respectively. The ASR decreased significantly. The burden of metabolic risk factor-associated CVDs was closely related to socioeconomic position and there were major geographical variations; additionally, men had a significantly greater disease burden than women, and the peak shifted later based on the age group. We predicted that the numbers of deaths and DALYs would reach 16.5 million and 324.8 million, respectively, by 2029.

Conclusions: The global burden of CVDs associated with metabolic risk factors is considerable and still rising, and more effort is needed to intervene in metabolic disorders.

Citing Articles

Mechanisms of inflammatory microenvironment formation in cardiometabolic diseases: molecular and cellular perspectives.

Liu M, Chen R, Zheng Z, Xu S, Hou C, Ding Y Front Cardiovasc Med. 2025; 11:1529903.

PMID: 39877020 PMC: 11772298. DOI: 10.3389/fcvm.2024.1529903.

Changing patterns of cardiovascular diseases and subtypes induced by kidney dysfunction among 25-64 years in China from 1992 to 2021.

Zeng G, Wang H, Cao P, Zhao J, Liu L, Guo H BMC Public Health. 2025; 25(1):26.

PMID: 39754057 PMC: 11697969. DOI: 10.1186/s12889-024-21183-4.

Implications for metabolic disturbances in myelodysplastic syndromes.

McGraw K, Larson D Semin Hematol. 2024; 61(6):470-478.

PMID: 39603905 PMC: 11646176. DOI: 10.1053/j.seminhematol.2024.11.004.

Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.

Psaltis J, Marathe J, Nguyen M, Le R, Bursill C, Marathe C Med Res Rev. 2024; 45(1):29-65.

PMID: 39139038 PMC: 11638809. DOI: 10.1002/med.22070.

References

Jagannathan R, Patel S, Ali M, Narayan K . Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors. Curr Diab Rep. 2019; 19(7):44. DOI: 10.1007/s11892-019-1161-2. View

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P . Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2019; 395(10226):795-808. PMC: 8006904. DOI: 10.1016/S0140-6736(19)32008-2. View

. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223-1249. PMC: 7566194. DOI: 10.1016/S0140-6736(20)30752-2. View

Mirabito Colafella K, Denton K . Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018; 14(3):185-201. DOI: 10.1038/nrneph.2017.189. View

Kjeldsen S . Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2017; 129:95-99. DOI: 10.1016/j.phrs.2017.11.003. View

. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. J Clin Lipidol. 2014; 8(1):29-60. DOI: 10.1016/j.jacl.2013.12.005. View

Arnold A, Cassis L, Eghbali M, Reue K, Sandberg K . Sex Hormones and Sex Chromosomes Cause Sex Differences in the Development of Cardiovascular Diseases. Arterioscler Thromb Vasc Biol. 2017; 37(5):746-756. PMC: 5437981. DOI: 10.1161/ATVBAHA.116.307301. View

Mills K, Bundy J, Kelly T, Reed J, Kearney P, Reynolds K . Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016; 134(6):441-50. PMC: 4979614. DOI: 10.1161/CIRCULATIONAHA.115.018912. View

10.

Hall J, do Carmo J, da Silva A, Wang Z, Hall M . Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019; 15(6):367-385. PMC: 7278043. DOI: 10.1038/s41581-019-0145-4. View

11.

Dahlof B . Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 2010; 105(1 Suppl):3A-9A. DOI: 10.1016/j.amjcard.2009.10.007. View

12.

Klop B, Elte J, Cabezas M . Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013; 5(4):1218-40. PMC: 3705344. DOI: 10.3390/nu5041218. View

13.

Kalra D . Homocysteine and cardiovascular disease. Curr Atheroscler Rep. 2004; 6(2):101-6. DOI: 10.1007/s11883-004-0097-3. View

14.

Ahmadi N, Mao S, Hajsadeghi F, Arnold B, Kiramijyan S, Gao Y . The relation of low levels of bone mineral density with coronary artery calcium and mortality. Osteoporos Int. 2018; 29(7):1609-1616. DOI: 10.1007/s00198-018-4524-7. View

15.

Lopez A, Adair T . Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. Int J Epidemiol. 2019; 48(6):1815-1823. DOI: 10.1093/ije/dyz143. View

16.

Powell-Wiley T, Poirier P, Burke L, Despres J, Gordon-Larsen P, Lavie C . Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021; 143(21):e984-e1010. PMC: 8493650. DOI: 10.1161/CIR.0000000000000973. View

17.

Costantino S, Paneni F, Cosentino F . Ageing, metabolism and cardiovascular disease. J Physiol. 2015; 594(8):2061-73. PMC: 4933114. DOI: 10.1113/JP270538. View

18.

Buttar H, Li T, Ravi N . Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. Exp Clin Cardiol. 2009; 10(4):229-49. PMC: 2716237. View

19.

North B, Sinclair D . The intersection between aging and cardiovascular disease. Circ Res. 2012; 110(8):1097-108. PMC: 3366686. DOI: 10.1161/CIRCRESAHA.111.246876. View

20.

. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019; 7(5):385-396. DOI: 10.1016/S2213-8587(18)30315-2. View